Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 943-945

  Zhang, Mengxian ^a,b,c   Lahn, Michael ^d   Huber, Peter E ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Combination therapy; Glioblastoma; Radiotherapy; Stem cells; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; INTEGRIN; LY 2109761; LY 2157299; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR SOX4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 84886943383     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19789     Document Type: Article

References (9)

1. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, et al. Blockade of TGFβ signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblasto-ma. Cancer Res 2011; 71:7155-67; PMID:22006998; http://dx.doi.org/10.1158/0008-5472.CAN-11-1212.
2. Rodon J, Baselga J, Calvo E, Seoane J, Brana I, Sicart E, et al. First Human Dose (FHD) Study of the oral transforming growth factor beta (TGFβ) receptor I kinase inhibitor LY2157299 in patients with treatment- refractory malignant glioma. ASCO MEETING ABSTRACTS, June 9, 2011; 3011.
3. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007; 11:147-60; PMID:17292826; http://dx.doi.org/10.1016/j.ccr.2006.11.023.
4. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, et al. TGFbeta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15:315-27; PMID:19345330; http://dx.doi.org/10.1016/j. ccr.2009.02.011.
5. Phillips HS, Kharbanda S, Chen R, Forrest W F, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression and resemble stages in neurogenesis. Cancer Cell 2006; 9:157-73; PMID:16530701; http://dx.doi.org/10.1016/j.ccr.2006.02.019.
6. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stemlike cells give rise to tumour endothelium. Nature 2010; 468:829-33; PMID:21102433; http://dx.doi.org/10.1038/nature09624.
7. Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res 2008; 28:1143-50; PMID:18505050.
8. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010; 16:461-73; PMID:20068105; http://dx.doi.org/10.1158/1078-0432.CCR-09-1983.
9. Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temo-zolomide and the novel TGFβ receptor I kinase inhibitor LY2109761. Neoplasia 2011; 13:537-49; PMID:21677877.